Astrazeneca PLC (NYSE:AZN)‘s stock had its “hold” rating reaffirmed by investment analysts at Beaufort Securities in a report issued on Friday.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald reaffirmed a “buy” rating on shares of Astrazeneca PLC in a research note on Thursday. Bank of America Corp. reiterated a “buy” rating and issued a $41.37 target price on shares of Astrazeneca PLC in a report on Thursday. Shore Capital reiterated a “hold” rating on shares of Astrazeneca PLC in a report on Thursday. Citigroup Inc. reiterated a “buy” rating on shares of Astrazeneca PLC in a report on Monday. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Astrazeneca PLC in a report on Wednesday, November 2nd. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating, ten have given a buy rating and two have given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $37.61.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Shares of Astrazeneca PLC (NYSE:AZN) opened at 27.68 on Friday. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The company’s 50-day moving average price is $30.74 and its 200 day moving average price is $30.85. The company has a market cap of $70.03 billion, a P/E ratio of 31.63 and a beta of 0.83.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, November 10th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.58. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The firm had revenue of $5.70 billion for the quarter, compared to the consensus estimate of $5.95 billion. During the same quarter in the prior year, the business earned $1.03 earnings per share. The company’s revenue was down 2.6% compared to the same quarter last year. Equities research analysts anticipate that Astrazeneca PLC will post $2.99 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. First Interstate Bank boosted its position in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares during the last quarter. Acrospire Investment Management LLC boosted its position in Astrazeneca PLC by 1,078.4% in the third quarter. Acrospire Investment Management LLC now owns 3,606 shares of the company’s stock worth $118,000 after buying an additional 3,300 shares during the last quarter. Synovus Financial Corp boosted its position in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares during the last quarter. Fifth Third Bancorp boosted its position in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares during the last quarter. Finally, Integrated Investment Consultants LLC boosted its position in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares during the last quarter. Hedge funds and other institutional investors own 11.35% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.